Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.35 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.35 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.35 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.35 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.35 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.35 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.35 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785305 | 1.00 | ROCK2 (0.39) | ROCK2CCR5F10MCHR1HCRTR1 | |
| SCHEMBL784956 | 0.93 | CCR5 (0.39) | ROCK2CCR5F10MCHR1KDM4E | |
| SCHEMBL785736 | 0.93 | CCR5 (0.39) | ROCK2CCR5F10MCHR1KDM4E | |
| SCHEMBL785665 | 0.88 | TAOK3 (0.41) | CCR5F10KDM4EPSMB11PSMA7 | |
| SCHEMBL784558 | 0.86 | ALDH1A1 (0.38) | ROCK2CCR5F10MCHR1PSMB11 | |
| SCHEMBL785435 | 0.84 | F10 (0.39) | ROCK2CCR5F10KDM4EMAPT | |
| SCHEMBL784149 | 0.84 | ROCK2 (0.38) | ROCK2CCR5F10MCHR1MAPT | |
| SCHEMBL784857 | 0.84 | CA12 (0.46) | ROCK2CCR5F10MCHR1KDM4E | |
| SCHEMBL784804 | 0.84 | F10 (0.41) | F10HCRTR1HCRTR2JAK2JAK1 | |
| SCHEMBL784256 | 0.83 | CCR5 (0.38) | ROCK2CCR5F10MCHR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | ROCK2 3995/4885CCR5 460/4885F10 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.